AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05641090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking in water
Description: Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
Study NCT05641090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No exercise intervention
Description: This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
Study NCT05590832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity of Whatsapp messages
Description: Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
Study NCT04899388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Block
Description: regional anaesthia
Study NCT04899388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Erector Spinae Plane Block
Description: regional anaesthia
Study NCT04899388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: intavenous
Study NCT04992650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Fat grafting
Study NCT05234372 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mivacunaLA
Description: Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
Study NCT05234372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mivacunaLA
Description: Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
Study NCT04626284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart Transplantation
Description: Heart Transplantation
Study NCT06093958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Manual loading of the chest wall
Description: The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
Study NCT05594771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural needle
Description: the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
Study NCT05594771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: the loading dose for labor analgesia administrated via epidural catheter
Study NCT05523830 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT06350149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Sweetened Beverages (SSB)
Description: The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.
Study NCT06350149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hi GI
Description: The Glycemic Index of the high-GI meals will be at least 75
Study NCT06350149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lo GI
Description: The Glycemic Index of the low- -GI meals will not be higher than 55.
Study NCT05371834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Treatment (Swift System)
Description: Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise.
Study NCT05371834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
Study NCT05655533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance Imaging scanners of sacroiliac joints.
Description: Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not
Study NCT05390307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide / Semaglutide
Description: Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
Study NCT05390307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 5-10 mg once daily for 6 months.
Study NCT05390307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide or Semaglutide / Dapagliflozin
Description: Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
Study NCT05390307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition
Description: Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
Study NCT05390307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual standard care
Study NCT05934955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1839100
Description: BI 1839100
Study NCT05934955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1839100
Description: Placebo matching BI 1839100
Study NCT05199519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IBI345
Description: IBI345 CAR-T cell injection by intravenous infusion
Study NCT05151510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigger point injection with 1% lidocaine
Description: Previously discussed in prior section.
Study NCT05151510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch 5%
Description: Will place lidocaine patch onto skin overlaying point of maximal tenderness
Study NCT06526182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab solution for injection administered subcutaneously.
Study NCT05059301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
Study NCT05142696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed
Study NCT06344663 — intervention group
Intervention type: OTHER
Intervention: motivational interview
Description: Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
Study NCT06444971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post isometric Relaxation
Description: Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid
Study NCT05111171 — intervention group
Intervention type: DEVICE
Intervention: sheath
Description: Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
Study NCT05142696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
Study NCT05142696 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
Study NCT05142696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
Study NCT05142696 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [68Ga]Ga-DOTA-TATE
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
Study NCT05142696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study NCT05142696 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carboplatin
Description: Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study NCT06365372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Western blot
Description: Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
Study NCT06047106 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: multiparametric MRI
Description: For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment.
Study NCT06047106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kidney graft biopsy
Description: Biopsy of the graft itself prior to transplantation in the recipient.
Study NCT06047106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant).
Study NCT05912361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: receiving a one hour theoretical and hands on training session before using an AI-based platform
Description: The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
Study NCT05142696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study NCT05608980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% hypochlorous acid
Description: once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
Study NCT05608980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily eyelid wipes for 2 weeks
Study NCT05142696 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Etoposide
Description: Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
Study NCT06047106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine specimens
Description: For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant).
Study NCT05246475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Simultaneous PET-MRI measurement
Study NCT06287242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
Study NCT04896619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kori tofu bread
Description: 34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
Study NCT04896619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein bread
Description: Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
Study NCT06346431 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DSPT - Digital Support for Problem-solving Therapy
Description: Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
Study NCT05474703 — intervention group
Intervention type: OTHER
Intervention: SF-36 Scores
Description: From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied.
Study NCT05611255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic Intermittent Catheterization
Description: A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
Study NCT05611255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Scan Guided Catheterization
Description: A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
Study NCT04804696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
Study NCT04804696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
Study NCT04804696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
Study NCT05656222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA combination treatment
Description: a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
Study NCT06275997 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Integration of Artificial Intelligence (AI) assistance to screening gastroscopy
Description: Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems.
Study NCT06275997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integration of Artificial Intelligence (AI) assistance to screening gastroscopy
Description: Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems.
Study NCT05834101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial Release
Description: Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs